Blar i forfatter "Kristiansen, Magnhild Gangsøy"
-
Association between brain-derived neurotropic factor (BDNF), high-sensitivity C-reactive protein (hs-CRP) and psychiatric symptoms in medicated and unmedicated patients
Soløy-Nilsen, Hedda; Nygård-Odeh, Kristin; Kristiansen, Magnhild Gangsøy; Brekke, Ole Lars; Mollnes, Tom Eirik; Reitan, Solveig Merete Klæbo; Øiesvold, Terje (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-02-03)Background - There is evidence that brain-derived neurotropic factor (BDNF) plays a protective role in the brain. Peripheral levels of BDNF correlate with its concentration in the brain. Previous studies have revealed lower serum BDNF levels in patients with mental illnesses. In most studies serum BDNF correlates negatively with psychiatric disorders and disease severity. Most studies in this field ... -
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
Kjellin, Midori; Kileng, Hege; Akaberi, Dario; Palanisamy, Navaneethan; Duberg, Ann-Sofi; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Nöjd, Johan Edvin; Aleman, Soo; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-08-19)<i>Background</i>: The NS5A resistance-associated substitution (RAS) Y93H is found quite frequently (5–10%) at baseline in direct-acting antiviral agents (DAA) treatment-naïve genotype (GT) 3a patients when studied by the population-sequencing method (cut-off 20%). This RAS may impair HCV DAA treatment response, since it possesses a high fold <i>in vitro</i> resistance to daclatasvir (DCV) and ... -
Future complications of chronic hepatitis C in a low-risk area: Projections from the hepatitis c study in Northern Norway
Kileng, Hege; Bernfort, Lars; Gutteberg, Tore Jarl; Moen, Odd Sverre; Kristiansen, Magnhild Gangsøy; Paulssen, Eyvind Jakob; Berg, Leif Kyrre; Florholmen, Jon; Goll, Rasmus (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-09-16)<i>Background</i>: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected individuals, which often remains undetected until cirrhosis and cirrhosis-related complications occur. Screening of high-risk subjects in Northern Norway has revealed a relatively low prevalence in the general population (0.24%). Despite this, late complications of HCV infection are increasing. ... -
Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy
Kileng, Hege; Kjellin, Midori; Akaberi, Dario; Bergfors, Assar; Duberg, Ann-Sofi; Wesslen, Lars; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-05)<i>Objectives</i>: Resistance-associated substitutions (RASs) may impair treatment response to direct-acting antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs (Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection on treatment outcome, with or without resistance-based DAA-treatment. This multi-center ... -
A rapid chemokine response of macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C
Florholmen, Jon; Kristiansen, Magnhild Gangsøy; Steigen, sonja eriksson; Sørbye, Sveinung Wergeland; Paulssen, Eyvind Jakob; Kvamme, J.M.; Zbigniew, Konopski; Gutteberg, tore jarl; Goll, Rasmus (Journal article; Tidsskriftartikkel; Peer reviewed, 2011)The role of chemokines in chronic hepatitis C virus (HCV) infection is not fully understood. The present study aimed to characterize the baseline serum concentrations and the initial β-chemokine response to treatment with interferon-α and ribavirin with respect to the final clinical outcome of virological response to treatment. Serum concentrations of alanine aminotransferase (ALT) and of the CC ...